Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma. Issue 2 (28th January 2023)

• Record Type: Journal Article
• Authors: Bici, Anisa; Pianko, Matthew J.; Nachar, Victoria R.
• Is Part Of: Leukemia & lymphoma. Volume 64:Issue 2(2023)
• Page Start: 407
• Page End: 414
• Publication Date: 2023-01-28
• Subjects: Infection -- multiple myeloma -- toxicity -- bacterial infections -- antibiotic prophylaxis -- pneumonia -- risk factors; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2138380
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Infections are an important cause of morbidity and mortality in newly diagnosed multiple myeloma (NDMM), but the real-world risk using modern induction regimens such as bortezomib, lenalidomide, and dexamethasone (RVd) is not well described. We performed a retrospective single-center cohort study to identify infections and risk factors in patients treated with first-line RVd from January 2014 to January 2020 and collected demographic and clinical data. Of 144 patients treated with RVd for NDMM, 21 patients (14.5%) experienced a bacterial infection during induction, of which 8 (5.5%) were grade 3 infections despite a low rate of antibiotic prophylaxis use (12%). Grade 3 neutropenia occurred in 11% of patients, 2% had febrile neutropenia and there were no deaths from infection. On multivariable analysis, age, smoking history, diabetes, antibiotic use in the 60 days preceding the start of RVd, and high-risk cytogenetics were associated with higher risk of bacterial infection.